“A GREAT OFFICE FOR LICENSING“ IAM MAGAZINE 2016
Proud to be ranked, again, by IAM Magazine (Intellectual Asset Management) as one of top 4 “highly recommended” Israeli firms in intellectual property transactions: “Horn & Co’s small size belies the reputation it enjoys with regard to the commercialisation of intellectual property.
Congratulations to our client, Zebra Medical for closing an impressive $30M financing round led by aMoon Ventures, with participation from Aurum, Johnson & Johnson Innovation and additional new and current investors.
Yuval Horn chosen as “Thought Leader” of Life Sciences Transactions by Who’s Who Legal: Life Sciences 2018.
Horn & Co. has been recognized again by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences.
Yuval Horn and Ohad Mamann of Horn & Co. represented Pontifax, who led a €16 million Series A round and restructuring in ABAC Therapeutics, Inc.
Yuval Horn, Paz Abercohen and Uri Dotan of Horn & Co. represented IOptima Ltd. and its shareholders, including Biolight Life Sciences Investments Ltd (TASE: BOLT) in a multi-stage acquisition transaction with an aggregate deal value of up to approximately $50 million, with Chengdu Kanghong Pharmaceutical Group, a Chinese life sciences company listed on the Shenzhen stock exchange.
Yuval Horn, Keren Kanir and Uri Dotan of Horn & Co. represented Vascular Biogenics Ltd. (Nasdaq: VBLT) in its $18.75 Million follow-on offering on NASDAQ.